What Illumina Shareholders Got Right

If Illumina sat on your watchlist instead of in your account, the past year may feel like an opportunity that slipped by. Holding Illumina over the past year would have returned 70.6%, including dividends. That outcome raises a sharper question. Back on 5 November 2025, when analysts were split on how fast NovaSeq X placements and clinical sequencing would scale, what clues in the record could have helped you judge whether that clinical adoption thesis was realistic?

The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.

Illumina is not the only name tied to this theme. Zero in on 34 healthcare AI stocks and compare how each one is priced.

The Two Illumina Stories Investors Had To Weigh

The shares cost US$122 at the start of the period, and Illumina sat between two very different yet plausible stories about where clinical sequencing and multiomics might head.

The bullish Narrative marked out a Fair Value of US$185. It rested on NovaSeq X and SomaLogic helping Illumina tap population genomics and precision medicine, with assumptions that revenue could grow 4.6% a year and the business might warrant a 27.7x P/E in 2028.

The more cautious view put Fair Value at US$112. That scenario still assumed 3.6% annual revenue growth but focused on risks from research budget pressure, China regulation, rising competition and a lower 18.4% profit margin.

What The Results Changed For The Illumina Thesis

Illumina’s Q3 2026 report showed revenue at US$1,129m and net income at US$220m, with net margin moving from 13.8% to 19.5%. That mix of higher sales and a fatter margin leaned toward the optimistic narrative that saw room for better profitability. Ongoing China and competition issues in the news kept the cautious case alive, so the evidence cut both ways.

The lesson here is simple. When a story hinges on clinical adoption and margin resilience, it is important to keep checking segment demand commentary and the reported net margin rather than assuming volume alone will carry the outcome.

What Illumina’s Rally Asks You To Believe Now

Illumina trades at US$208 today after a 70.6% gain over the past year. The selected Narrative’s Fair Value sits below that price, so it treats the current valuation as demanding rather than cheap.

That Narrative leans on clinical sequencing strength but questions how much margin and consumables upside is left. Anyone buying now has to judge whether Illumina can keep converting clinical consumables demand into durable earnings despite legal, cost and competition pressures.

"The numbers imply that Illumina's share price already reflects optimistic assumptions on revenue growth, consumables pull through, and margin expansion that leave limited room for disappointment."

That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for

Before The Next Story Makes Headlines

You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.

• Company 1 - 33% below our estimate - build liquid cooling and power systems for rapidly scaling AI data centers.
• Company 2 - 29% below our estimate - expand digital banking, payments and microfinance access for underserved credit customers.
• Company 3 - 21% below our estimate - connect and protect dense electrical and data infrastructure within modern power networks.

Three companies from the same screener. Open all 42 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com